News | Proton Therapy | February 10, 2017

Worldwide Survey Says Proton Therapy Will Continue to Grow Rapidly

Proton therapy seen as more efficacious for various cancers than seven years ago

state of the proton therapy market entering 2017, proton therapy, radiation therapy, Robust Insight survey

February 10, 2017 — Independent market research consultancy Robust Insight recently conveyed a survey commissioned by IBA on the state of the proton therapy market entering 2017. The report is based on an online survey among 1,200 hospitals in order to assess how they view proton therapy today and in the future.

Two hundred twenty-two replies from professionals in radiation oncology were received from 205 institutions in 29 countries. Thirty-six percent of the respondents were from centers performing proton therapy. The main highlights of the study are:

  • Sixty-eight percent of respondents believe that proton therapy will continue to grow rapidly in the future;
  • Eighty-two percent of respondents were aware that proton therapy has lower risk of treatment-induced disorders versus conventional radiation therapy;
  • Compared to a similar study in 2009, proton therapy is seen as more efficacious in 2016 than in 2009 for cancers like pediatric, base-of-skull treatment, lung and prostate;
  • Just over 50 percent of the respondents cite limited clinical evidence and limited reimbursement for proton therapy as the biggest barriers impacting the growth of the field; 
  • Seventy-seven percent of respondents believe there will be more and more clinical evidence demonstrating the benefits of proton therapy; and
  • Seventy-three percent believe that the availability of proton therapy will have a growing impact on centers’ reputation.

For more information:

Related Content

Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa
Advanced Radiation Therapy Upgrades AccuBoost Digital Brachytherapy Platform
News | Brachytherapy Systems, Women's Healthcare | October 23, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago, Advanced Radiation...
MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment
News | Treatment Planning | October 18, 2019
The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an...
Videos | Radiation Oncology | October 11, 2019
Lorraine Drapek, DNP, nurse practitioner, radiation oncology, GI service,...
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
ProTom International received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radiance 330 proton therapy system
News | Proton Therapy | October 07, 2019
ProTom International received 510(k) clearance from the U.S.